Profile data is unavailable for this security.
About the company
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-6.47m
- Incorporated2014
- Employees10.00
- LocationMonopar Therapeutics Inc1000 Skokie Blvd Ste 350WILMETTE 60091-1146United StatesUSA
- Phone+1 (847) 388-0349
- Fax+1 (302) 655-5049
- Websitehttps://www.monopartx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicinova Inc | 0.00 | -10.29m | 98.09m | 13.00 | -- | 1.78 | -- | -- | -0.2099 | -0.2099 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | -16.31 | -15.36 | -17.03 | -15.90 | -- | -- | -- | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Anixa Biosciences Inc | 0.00 | -12.36m | 98.47m | 4.00 | -- | 4.52 | -- | -- | -0.3906 | -0.3906 | 0.00 | 0.6772 | 0.00 | -- | -- | 0.00 | -50.54 | -59.69 | -52.50 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -42.77m | 98.55m | 47.00 | -- | 4.11 | -- | -- | -0.8066 | -0.8066 | 0.00 | 0.4503 | 0.00 | -- | -- | 0.00 | -50.37 | -48.44 | -54.67 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.6859 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Leap Therapeutics Inc | 0.00 | -64.82m | 98.72m | 54.00 | -- | 2.02 | -- | -- | -1.93 | -1.93 | 0.00 | 1.28 | 0.00 | -- | -- | 0.00 | -87.23 | -80.06 | -106.79 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Fractyl Health Inc | 97.00k | -68.97m | 98.73m | 102.00 | -- | 1.97 | -- | 1,017.84 | -1.43 | -1.43 | 0.002 | 1.05 | 0.0011 | 0.698 | 8.08 | 950.98 | -68.48 | -- | -78.83 | -- | 46.39 | -- | -64,849.48 | -- | 5.57 | -- | 0.376 | -- | -- | -- | -48.15 | -- | -- | -- |
| Immunic Inc | 0.00 | -96.90m | 99.99m | 77.00 | -- | 2.43 | -- | -- | -1.24 | -1.24 | 0.00 | 0.4576 | 0.00 | -- | -- | 0.00 | -147.12 | -72.09 | -213.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Avalo Therapeutics Inc | 820.00k | -8.14m | 100.30m | 19.00 | -- | 4.43 | -- | 122.32 | -10.96 | -10.96 | 0.1976 | 2.35 | 0.0128 | -- | 0.6467 | 43,157.89 | -12.46 | -99.64 | -26.07 | -154.42 | 182.20 | 84.69 | -970.49 | -613.58 | -- | -6.69 | 0.00 | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Coya Therapeutics Inc | 9.55m | -10.70m | 101.58m | 8.00 | -- | 2.89 | -- | 10.63 | -0.6928 | -0.6928 | 0.687 | 2.10 | 0.4027 | -- | -- | 1,194,290.00 | -45.10 | -- | -49.39 | -- | -- | -- | -111.98 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Monopar Therapeutics Inc | 0.00 | -6.47m | 104.03m | 10.00 | -- | 14.05 | -- | -- | -1.99 | -1.99 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -88.32 | -54.07 | -112.04 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 203.41k | -112.88m | 105.41m | 122.00 | -- | 1.44 | -- | 518.24 | -4.49 | -4.49 | 0.008 | 2.82 | 0.0014 | -- | 0.2184 | 1,667.30 | -75.21 | -59.52 | -96.91 | -71.29 | -- | -- | -55,491.91 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Century Therapeutics Inc | 2.69m | -129.89m | 105.44m | 152.00 | -- | 0.5358 | -- | 39.27 | -1.86 | -1.86 | 0.0372 | 2.31 | 0.0068 | -- | -- | 17,664.47 | -33.04 | -- | -34.83 | -- | -- | -- | -4,837.73 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| INmune Bio Inc | 42.00k | -41.27m | 105.54m | 11.00 | -- | 2.73 | -- | 2,512.88 | -2.18 | -2.18 | 0.0022 | 1.74 | 0.0007 | -- | 0.0228 | 3,818.18 | -71.48 | -37.82 | -94.55 | -41.86 | -- | -- | -98,266.66 | -14,901.03 | -- | -34.08 | 0.0606 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 107.34m | 9.00 | -- | 18.06 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -28.17m | 109.36m | 140.00 | -- | 35.26 | -- | -- | -1.06 | -1.06 | 0.00 | 0.0579 | 0.00 | -- | -- | 0.00 | -96.37 | -- | -165.17 | -- | -- | -- | -- | -- | -- | -16.57 | 0.8306 | -- | -- | -- | -11.06 | -- | -- | -- |
| Alto Neuroscience Inc | 0.00 | -57.45m | 110.26m | 88.00 | -- | 0.6683 | -- | -- | -2.42 | -2.42 | 0.00 | 6.12 | 0.00 | -- | -- | 0.00 | -46.93 | -- | -51.10 | -- | -- | -- | -- | -- | -- | -- | 0.0649 | -- | -- | -- | -31.02 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Monopar Therapeutics Inc's reporting currency: US Dollar USD
24.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 31 Oct 2024 | 562.48k | 10.66% |
| RA Capital Management LPas of 24 Oct 2024 | 511.21k | 9.69% |
| Tang Capital Management LLCas of 24 Oct 2024 | 200.00k | 3.79% |
| Geode Capital Management LLCas of 30 Sep 2024 | 14.07k | 0.27% |
| Virtu Americas LLCas of 30 Jun 2024 | 3.77k | 0.07% |
| NewEdge Advisors LLCas of 30 Sep 2024 | 600.00 | 0.01% |
| UBS Securities LLCas of 30 Sep 2024 | 512.00 | 0.01% |
| Wells Fargo Clearing Services LLCas of 30 Sep 2024 | 500.00 | 0.01% |
| Desjardins Securities, Inc.as of 30 Sep 2024 | 16.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2024 | 13.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
